
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is a rapidly growing life science company with a strong focus on providing specialized bioproduction tools for the cell and gene therapy industry. With a projected revenue increase of 13.6% in the current quarter and 21% for the full year 2026, as well as a positive earnings per share of $0.05, BioLife Solutions shows strong financial performance. The recent acquisition by Repligen and the company's strategic focus on biopreservation media and cryopreservation workflow further solidify its position as a leader in the sector.
Bears say
BioLife Solutions is facing increasing competition in the biopreservation market, which may lead to a decline in market share and revenue growth. The company's recent acquisition by Repligen may limit potential future growth opportunities and the expected synergies may not come to fruition. Additionally, regulatory and liquidity risks may also hinder the company's growth and profitability.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares